BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher
BioDelivery Sciences International, Inc. BDSI was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $1.95–$2.25 in the past one-month time frame, witnessed a sharp increase yesterday.
BioDelivery Sciences has seen the Zacks Consensus Estimate for the current quarter being revised downward over the past two months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
BioDelivery Sciences currently has a Zacks Rank #3 (Hold) while its Earnings ESPis 0.00%.
BioDelivery Sciences International, Inc. Price and Consensus
BioDelivery Sciences International, Inc. Price and Consensus | BioDelivery Sciences International, Inc. Quote
Another stock in the Medical - Biomedical and Genetics industry is Protagonist Therapeutics, Inc. PTGX which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is BDSI going up? Or down? Predict to see what others think: Up or Down
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioDelivery Sciences International, Inc. (BDSI) : Free Stock Analysis Report
Protagonist Therapeutics, Inc. (PTGX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
